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ABSTRACT
EXAMINING THE ASSOCIATION BETWEEN PSYCOTROPIC MEDICATION
USAGE AND SUICIDAL DESIRE AND RISK
by Brittney LeAnn Assavedo
December 2015
The primary aim of this study was to examine the relationship between
components of suicidal desire and psychotropic medication. Specifically, the usage of
psychotropic medication, the usage of specific classes of psychotropic medications and
the amount of psychotropic medication utilized, and differences in feelings of perceived
burdensomeness, thwarted belongingness, and overall suicide risk were examined. The
present study utilized pre-collected data consisting of 225 patients with substance use
disorder, who are undergoing residential treatment for substance dependence. It was
posited that individuals utilizing psychotropic medications would exhibit higher mean
levels of thwarted belongingness, perceived burdensomeness, and suicide risk relative to
individuals not utilizing psychotropics and that individuals utilizing multiple
psychotropic medications would exhibit higher suicidal desire and risk than individuals
utilizing zero or one psychotropic medication. Additionally, it was posited that
individuals utilizing antipsychotics would exhibit higher suicidal desire and risk than
individuals utilizing any other type of psychotropic medication. For all hypotheses, it
was posited that such effects would occur above and beyond severity of psychopathology
and substance use. Results indicated a significant difference in suicide risk between
individuals utilizing a psychotropic and individuals not utilizing a psychotropic.
Additional exploratory analyses indicated a significant difference in levels of perceived
ii

burdensomeness between individuals utilizing an antidepressant and individuals utilizing
any other type of psychotropic besides an antidepressant. Overall, results suggest that the
use of psychotropic medication may increase the risk for suicide. These findings
highlight the need for routine suicide risk assessments for patients utilizing psychotropic
medications.
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CHAPTER I
INTRODUCTION
Suicide is a significant public health concern in the U.S., serving as the tenth
leading cause of death in 2013 (Centers for Disease Control and Prevention [CDC],
2015). A systematic review examining 15,629 cases of suicide in the general population
between 1959 and 2001 suggested that 98% of individuals who died by suicide had a
diagnosable mental disorder (Bertolote & Fleischmann, 2002). Indeed, mental illness is a
known risk factor for suicide, and suicidality is often treated through interventions aimed
at addressing specific mental disorders.
One approach to intervention commonly utilized for treating suicidal individuals
is psychopharmacology, which can include numerous classes of drugs targeting a wide
range of mental disorders; however, the evidence regarding the suicide prevention
capabilities of psychotropic medications is mixed (Ernst & Goldberg, 2004). For
example, Rissanen et al. (2012) found that individuals taking antipsychotics for longer
periods of time exhibited more suicidal ideation relative to individuals taking
antipsychotics for shorter periods of time, even after accounting for symptoms of
depression and anxiety. Additionally, accounting for other psychiatric symptoms, the
dosage of antipsychotic medication was significantly associated with suicidal ideation
among individuals with non-psychotic diagnoses, such that higher doses were correlated
with more suicidal ideation. No consistent mechanism has been proposed for the studies
mentioned above, further underscoring the inconsistency in the evidence for suiciderelated outcomes with respect to pharmacological treatment.
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In addition to their association with suicidal ideation, psychotropics also
potentially play a role in suicidal behavior. Succeeding unspecified and medicinal
substances, psychotropic medications are the most common agent utilized for intentional
overdoses, which is the most common method of suicide attempt and self-inflicted injury
among individuals requiring an Emergency Department visit as a result of such incidents
(Ting, Sullivan, Boudreaux, Miller, & Camargo, 2012). In 2011, benzodiazepines,
antidepressants, and antipsychotics were utilized in approximately 62% of suicide
attempts (Substance Abuse and Mental Health Services Administration, 2013). Indeed,
many psychotropic medications are labeled with a black box warning indicating potential
risk of suicidal ideation or behavior for consumers (e.g. antidepressants, antiepileptics,
Atomoxetine; Hassan, 2012). Although prior studies have established the existence of a
relationship between psychotropic medication and suicidality, research examining the
nature of such a relationship is lacking; thus, empirical research investigating
mechanisms and relevant contextual factors of psychotropic medication use associated
with suicidality is essential for prevention of problematic outcomes and mitigation of
consequences.
One theoretical framework that may provide a method for understanding the
nature of the relationship between psychotropic medications and suicidality is the
interpersonal-psychological theory of suicidal behavior (IPTS; Joiner, 2005). The theory
posits that, in addition to the ability to die by suicide, an individual must possess a desire
for suicide in order to enact lethal self-harm. This desire for suicide is comprised of the
simultaneous presence of two psychological states: perceived burdensomeness (PB) and
thwarted belongingness (TB). PB is an individual’s sense that he/she is a burden and
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liability to family, friends, and/or society and the belief that one’s death is worth more to
others than their continued life. TB is an individual’s sense that he/she lacks meaningful
connections with others.
As suggested by Van Orden et al.’s (2010) hierarchical latent variable model, PB
is comprised of a belief of liability and cognitions of self-hatred. In this model, factors
such as low self-esteem, shame, and unemployment result in feelings of PB. The
hierarchical latent variable model also suggests that TB is comprised of both loneliness
and the absence of reciprocally caring relationships. In this model, factors such as low
social support, living alone, divorce, and social withdrawal result in feelings of TB. A
longitudinal study examining factors associated with psychotropic medication use at three
time points within 17 years found that non-clinical characteristics predicted psychotropic
medication use (Colman, Croudace, Wadsworth, & Jones, 2008). Specifically,
unemployment and lack of social support were associated with the use of antidepressants,
anxiolytics, and hypnotics above and beyond the effects of the severity of
psychopathology. Unemployment significantly predicted psychotropic medication use at
both time 1 and time 3; whereas, living alone, divorce and separation significantly
predicted psychotropic medication use at time 3.
Although several psychotropic medications are efficacious in the reduction of
symptoms associated with particular psychopathological disorders, the use of these
medications is often accompanied by adverse side effects (Murray, 2006; Ponterotto,
1985). Neurological disorders, confusion and disorientation, hallucinations, anxiety,
depression, irritability, hostility, and anger have been associated with the use of
benzodiazepines (Maxmen & Ward, 1995). Antidepressants, specifically Selective
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Serotonin Reuptake Inhibitors, have been reported to induce extrapyramidal symptoms
such as akathaisia, dystonia, parkinsonism, and tardive dyskinesia (Leo, 1996).
Increasing incidence of tardive dyskinesia was found to be associated with antipsychotic
use over time (Glazer, 2000). In a clinical sample of 362 adults, tardive dyskinesia was
experienced by approximately 32% of individuals using antipsychotics for 5 years or less,
57% using antipsychotics for 10 to 15 years, and 68% with 20 to 25 years of use. In a
study examining the regional brain activity of participants performing cognitive tasks
succeeding treatment with mood stabilizers, results indicated that lithium and valproate
caused cognitive impairments in individuals with no previous consumption of mood
stabilizers (Bell, Willson, William, Dave, & Silverstone, 2005).
Psychopharmacotherapy is often negatively stereotyped by individuals whom are
unfamiliar with psychotropics, as one study found that individuals who had never utilized
a psychotropic medication displayed significantly more negative attitudes towards and
beliefs about psychotropic medication than either psychiatric or substance abuse
outpatients (Fife, Ketzenberger, & Olson, 2012). Similarly, upon examination of public
opinions and beliefs regarding treatment of depression, Ozmen and colleagues (2005)
found that the public considered pharmacotherapy an ineffective treatment for
depression. Furthermore, among the 213 participants, 62.1% believed that antidepressant
treatment may result in addiction.
In concordance with the negative view, stigmatization is often associated with
psychopharmacology. A study investigating stigmatization among adolescents utilizing
psychiatric medication discovered thematic constructs that commonly emerged among
such adolescents (Kranke, Floersch, Townsend, & Munson, 2009). Adolescents taking
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antipsychotic medication often felt a sense of shame associated with taking medication.
Furthermore, adolescents perceiving non-acceptance from peers resulting from
medication usage withdrew from peer interactions. Additionally, a study examining
patients’ personal experiences in regards to medication-induced stigmas discovered that
patients with schizophrenia receiving medication treatment felt most stigmatized in areas
of employment due to side effects of medication (e.g. others perceive work performance
as being impaired; Novak & Švab, 2009). Examining the perception of stigma among
outpatients receiving antidepressants, Interian, Martinez, Guarnaccia, Vega, and Escobar
(2007) found that the use of antidepressants was associated with negative attributes such
as weakness and inability to cope with problems.
The primary aim of the study is to investigate the association between
psychotropic medication usage and suicidal desire and risk in a sample of adults
receiving residential treatment for substance use disorders. Given the adverse side effects
of psychotropic medications and the stigmatizing effects associated with their usage, we
hypothesize that individuals utilizing psychotropic medications will exhibit higher mean
levels of PB, TB and suicide risk relative to individuals not utilizing psychotropics, above
and beyond the effects of the severity of psychopathology. Additionally, we posit that
individuals utilizing multiple psychotropic medications will exhibit higher mean levels of
PB, TB and suicide risk in contrast to individuals utilizing one or zero psychotropic
medication, again controlling for severity of psychopathology. Finally, we hypothesize
that individuals utilizing antipsychotics will exhibit higher mean levels of PB, TB, and
suicide risk than individuals utilizing psychotropic medications from any other
classification (i.e. antidepressants, anxiolytics, or mood stabilizers). Here again, we will
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control for severity of psychopathology. Effective mental health treatment for
psychological disorders such as depressive, bipolar spectrum, and schizophrenic
disorders often involves pharmacological therapy (e.g. Baghai et al., 2011; Culver,
Arnow, & Ketter, 2007; Marder, 2000), and results consistent with hypotheses would
suggest that individuals prescribed such medications may experience elevated levels of
suicidal desire and risk; therefore, suggesting the need for routine suicide risk assessment
in such individuals. The proposed study does not intend to advocate against the use of
psychopharmacology, but rather suggests closer monitoring of individuals utilizing
psychotropic medication. Although not all individuals utilizing such medication
experience an increased risk for suicide, some individuals may experience increases in
certain elements of risk. Understanding the nature of the relationship between
psychotropic medication and suicidality may allow for the reduction of risks in such
individuals.
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CHAPTER II
METHOD
Participants
Participants included 225 patients with substance dependence (50.2% male)
undergoing treatment in a residential Substance Use Disorder (SUD) treatment facility.
Participants ranged in age from 18 to 65 years (Mage = 34.36). Regarding participant
ethnicity: 59.6% identified as White, 36.4% as African American, 1.3% as
Hispanic/Latino, and 1.3% identified as another racial/ethnic background. Regarding
participants’ educational attainment: 27.1% had not completed high school or received a
GED, 33.7% received a high school diploma or GED, and 8.8% graduated from college.
Demographic information is included in Table 1. Inclusion criteria for the current study
consisted of information pertaining to the use of a psychotropic medication (presence
versus absence) and, for those who endorsed currently taking psychotropic medications,
the name of the psychotropic medication(s) being utilized. Approximately half of the
participants (n =112) were utilizing some form of prescribed psychotropic medication:
36% utilized an antidepressant, 11% utilized an anxiolytic, 11% utilized a mood
stabilizer, and 10% utilized an antipsychotic. Additionally, 32.4% utilized medication
from a single class of psychotropics, 13.8% utilized medication from two classes of
psychotropic medication, and 2.7% utilized medication from three classes of
psychotropic medication (see Table 2). Risk for suicide was diverse within this sample,
with majority of the sample (58.7%) endorsing at least a low risk for suicide and 38.7%
endorsing no risk for suicide.
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Table 1
Demographic Information

Race
White/Caucasian
Black/African American
Asian/Southeast Asian
Hispanic/Latino
Native American
Education
Less than High School
High School Graduate/G.E.D.
Some College
College Graduate
Some Graduate School
Graduate or Professional Degree

N = 222
59.6
36.4
0.4
1.3
0.9
N = 221
27.5
33.7
22.7
6.2
1.3
1.3

Relationship Status
Single
Living with a partner
Married but separated
Married

N = 221
60.0
12.4
10.7
15.1

Income
0 - 19,999
20,000 - 39,999
40,000 - 59,999
60,000 - 79,999
80,000 - 99,999
100,000 or more

N = 218
65.3
14.7
7.6
4.0
1.7
3.6

Table 2
Psychotropic Medication Information
Variable
Number of Psychotropic Medications
0
1
2
3
4
5

Percentage (N = 225)
51.1
29.8
14.2
4.0
0.4
0.4

Number of Psychotropic Classes
0
1
2
3

51.1
32.4
13.8
2.7

Class of Psychotropic Medication Used
Antidepressant
Antipsychotic

36.0
10.2
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Table 2 (continued).
Variable

Percentage (N= 225)

Anxiolytic
Mood Stabilizer

11.1
10.7

Table 3
Diagnostic Information
DSM-IV Diagnosis
Generalized Anxiety Disorder
Panic Disorder without Agoraphobia
Posttraumatic Stress Disorder
Social Phobia
Antisocial Personality Disorder
Borderline Personality Disorder
Obsessive-Compulsive Personality Disorder
Anorexia Nervosa
Bulimia Nervosa
Major Depressive Episode

Percent of Individuals with Diagnosis
32.0
24.9
24.9
23.1
38.7
33.3
12.4
0.4
7.6
25.8

Measures
Diagnostic and Clinical Interviews
Substance Use Disorders. The Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders, fourth edition (DSM-IV), Axis I Disorders
(SCID-I/P; First, Spitzer, Gibbon & Williams, 1996) is a structured diagnostic interview
assessing both current and lifetime DSM-IV Axis I disorders. In the current study, the
SCID-I/P was used to assess SUDs. The SCID-I/P has demonstrated adequate inter-rater
and test-retest reliability (Lobbestael, Leurgans, & Arntz, 2011). Diagnostic frequencies
are included in Table 3.
Axis I Disorders. The Mini International Neuropsychiatric Interview, Version 6.0
(MINI; Sheehan et al., 2009) is a short structured diagnostic interview assessing current
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DSM-IV Axis I disorders. In the current study, the MINI was used to assess DSM-IV
Axis I disorders, with the exclusion of posttraumatic stress disorder (PTSD) and SUDs.
The MINI has demonstrated adequate reliability and validity in its assessment of
psychiatric disorders, as well as strong test-retest and inter-rater reliability (Sheehan et
al., 1997).
Predictors
Psychotropic Medication Usage. Participants were asked, “Are you currently
taking any medications for a psychiatric disorder?” Answers were structured as yes
versus no. Responses were coded as 0 if participants did not endorse the use of a
psychotropic medication, and as 1 if participants endorsed the use of a psychotropic
medication.
Number of Psychotropic Medications. Participants who endorsed the use of
psychotropic medications were asked to provide the names of the psychotropic
medications currently being used. Researchers verified if the medication name provided
was actually a psychotropic, and responses were coded on the basis of the number of
psychotropic medication names provided. Responses ranged from 1 (use of a single
psychotropic medication) to 5 (use of five psychotropic medications).
Antipsychotic Usage. Based on the names of the psychotropic medications
provided by participants each medication was coded into its respective classification (i.e.
antidepressant, anxiolytic, antipsychotic, or mood stabilizer). Medications were coded as
1 if the medication was within the class and 0 if the medication was not in that class.
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Outcomes
Perceived Burdensomeness and Thwarted Belongingness. The Interpersonal
Needs Questionnaire-10-Item Version (INQ-10; Van Orden, Cukrowicz, Witte, & Joiner,
2012) is a self-report questionnaire assessing the components comprising suicidal desire
as conceptualized by the IPTS. Items are scored on a Likert scale ranging from 1 (Not at
all true for me) to 7 (Very true for me), with higher scores indicating greater risks for
these two components. Although less commonly used than the INQ-15, this version of
the measure has demonstrated comparable psychometric properties (Hill et al., 2014).
Alpha equaled 0.88 for the perceived burdensomeness subscale and 0.72 for thwarted
belongingness.
Risk for Suicide. The MINI was again utilized to assess current (past month)
suicide risk and attempt history. The MINI includes 11 items assessing a variety of
suicide risk factors present within the past month: (1) experience of an accident in which
the individual intended to injure themselves or die, (2) hopelessness, (3) thoughts of
being better off dead, (4) a desire to harm oneself, (5) thoughts about suicide, (6)
difficulties controlling impulses to end one’s life, (7) presence of a suicide plan, (8)
actions taken in preparation to injure or kill oneself, (9) past month non-suicidal selfinjury, (10) a past month suicide attempt, (11) a lifetime suicide attempt. A score is
obtained by summing the values from the endorsed items. Scores can range from 0 (no
risk) to 52 (high suicide risk). The MINI suicidal risk index has been shown to predict
suicidal behaviors over the course of one year (Roaldset, Linaker, & Bjørkly, 2012).
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Covariates
Depressive & Anxiety Symptom Severity. The Depression, Anxiety, Stress Scale
(DASS-21; Lovibond & Lovibond, 1995) is a 21-item self-report questionnaire designed
to assess the unique symptoms of depression, anxiety, and stress. Items are rated from 0
(did not apply to me at all) to 3 (applied to me very much, or most of the time). The
Depression scale was utilized to assess the severity of dysphoria, hopelessness,
devaluation of life, self-deprecation, lack of interest, anhedonia, and inertia experienced
within the past week. The Anxiety scale was utilized to assess the severity of irritability,
agitation, difficulty relaxing, and impatience experienced within the past week.
Depression and anxiety symptom severity were utilized as covariates to ensure that the
severity of psychopathology was not a better explanation for higher rates of suicidal
desire than was psychotropic medication usage. The DASS has demonstrated adequate
psychometric properties (Antony, Bieling, Cox, Enns, & Swinson, 1998). The alpha
coefficient was 0.90 for the depression subscale and 0.84 for the anxiety subscale.
Borderline Personality Disorder (BPD) Symptom Severity. The Borderline
Evaluation of Severity Over Time (BEST; Pfohl et al., 2009) is a 15-item, self-report
measure of past month BPD symptom severity. Items 1 through 12 are rated from 1 (no
distress) to 5 (extreme distress), and items 13 through 15 are rated from 1 (almost never)
to 5 (almost always). The BEST has demonstrated adequate reliability and validity
(Pfohl et al., 2009). BEST scores were included to account for severity of BPD symptom
severity. Internal consistency in our analysis was 0.83.
Substance Use Severity. The Drug Use Questionnaire (DUQ; Hien & First, 1991)
is a 10-item, self-report questionnaire assessing frequency of alcohol and drug use over
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the past year. Item responses are summed, creating an overall score representative of
past-year substance use frequency for various substances. The overall score for
substance use frequency did not include the frequency of nicotine use in this study. The
DUQ has demonstrated good convergent validity with structured interview diagnoses in
association with relevant clinical outcomes (Lejuez, Bornvalova, Reynolds, Daughters, &
Curtin, 2007). Here again, DUQ scores were included to account for the impact of the
severity of psychopathology.
Demographics
Demographic covariates were determined empirically by testing for
significant associations between the predictor and outcome variables and gender, race,
age, education level, employment status, marital status, and total household income.
Procedures
All procedures were reviewed and approved by the relevant Institutional Review
Boards prior to the onset of data collection. Data was collected as part of a broader study
examining risky behaviors among SUD patients (N = 226). Inclusion criteria for the
initial study included: cocaine and/or alcohol dependence, a Mini-Mental Status Exam
(MMSE; Folstein, Folstein, & McHugh, 1975) score of ≥ 24, and absence of current
psychotic disorders. In order to produce a sample with negligible withdrawal effects,
eligible participants were recruited for participation no sooner than 72 hours from entry
into the treatment facility. Additionally, patients were also required to undergo
detoxification from an external source prior to entry into treatment, further reducing
potential confounds related to withdrawal. The initial study was completed over a total
of three sessions. All of the data used in the current study were collected in the first
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session of the initial study, and data unrelated to the current study were collected in the
remaining two sessions (e.g. heart rate variability, cortisol levels, and distress levels).
One participant from the original study was not included in the current study due to lack
of information regarding the use of psychotropic medication.
Data Analytic Procedures
In order to test our hypotheses, nine Analyses of Covariance (ANCOVAs) were
conducted. PB served as the outcome variable within three analyses, TB served as the
outcome variable in three analyses, and suicide risk served as the outcome variable in the
remaining three analyses. Within all nine analyses, severity of psychopathology was
accounted for by including depression, anxiety, BPD severity, and frequency of substance
use as covariates. Additionally, for analyses in which PB was the outcome variable, TB
was included as a covariate. For analyses in which TB was the outcome variable, PB was
included as a covariate. The use of psychotropic medication (none vs. 1+) served as the
predictor variable for the first three analyses and the number of psychotropic medications
(none or one vs. 2+) utilized served as the predictor variable for the second three
analyses. Finally, the use of an antipsychotic (vs. use of other psychotropics) served as
the predictor variable for the final three analyses examining the association between
antipsychotics and suicidal desire. In the final analysis, only individuals currently
prescribed one or more psychotropic medications were included.
In an effort to increase specificity, an exploratory analysis consisting of nine
ANCOVAs was conducted. The use of an antidepressant (versus use of other
psychotropics) served as our predictor in the first three analyses, the use of an anxiolytic
served as the predictor in the second three analyses, and the use of a mood stabilizer
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served as the predictor for the final three analyses. Again, PB, TB, and suicide risk
served as the outcome variables, and depression, anxiety, and BPD severity were
included as covariates.
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CHAPTER III
RESULTS
Examination of Distributions
PB, TB, and suicide risk all exhibited significant skew and/or kurtosis and were
thus rank transformed using Blom’s formula to better approximate a normal distribution.
Selection of Covariates
In order to determine the appropriate covariates to be included within analyses, a
series of analyses of variance (ANOVA) were utilized to determine between group
differences in PB, TB, and suicide risk for the demographic variables sex, race,
employment status, and relationship status. ANOVAs were also conducted to determine
if significant differences in psychotropic medication use, number of psychotropic
medications used, and antipsychotic use existed for continuous demographic variables
(age, total family income, and education level). Results indicated significant differences
between the various statuses of employment for suicide risk (F (5, 213) = 2.67, p < 0.05)
and educational levels for psychotropic medication use (F (9, 211) = 2.29, p < 0.05) and
number of psychotropic medication used (F (9, 211) = 3.00, p < 0.01). No other between
group differences were significant.
Next, a series of chi-square analyses were utilized to determine if significant
differences in psychotropic medication use, number of psychotropic medications used
and antipsychotic use existed for sex, race, employment status, and relationship status.
Results indicated that gender (χ2(1, N = 222) = 16.24, p < 0.01) and race (χ2(4, N = 222)
= 17.81, p < 0.01) were significantly associated with psychotropic medication use.
Additionally, gender (χ2(1, N = 222) = 9.12, p < 0.01) and race (χ2(4, N = 222) = 17.81, p
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< 0.01) were significantly associated with number of psychotropic medications used. No
other chi-square analyses were significant.
Finally, zero-order correlations were used to examine associations between
continuous demographic variables (age, total family income, and education level) and
TB, PB and suicide risk. Results revealed significant correlations between education
level and TB (r = 0.17, p < 0.05). No other zero-order correlations were significant.
In summary, depression, anxiety and BPD severity and frequency of substance
abuse not including nicotine were included as covariates in all analyses. Gender, race,
and education level were included as covariates for all analyses involving psychotropic
medication use and number of psychotropic medications used. Education was also
included in analyses involving PB, and employment status was included in all analyses
involving suicide risk.
Primary Analyses
In order to test hypotheses, three series of ANCOVAs were conducted. The first
series of ANCOVAs assessed whether the use of psychotropic medication was associated
with higher mean levels of TB, PB, and suicide risk. Results revealed a statistically
significant difference in suicide risk (F(9, 191) = 9.62, p < 0.01) between individuals
utilizing one or more psychotropic medications and individuals not utilizing a
psychotropic medication, accounting for gender, race, employment status, education
level, and severity of psychopathology and substance use. Results also revealed nonsignificant differences in PB (F(9, 187) = 0.067, p = 0.80) and TB (F(9, 187) = 0.015, p =
0.90) between individuals utilizing at least one psychotropic medication and individuals
utilizing no psychotropic medications (Table 4).
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The second series of ANCOVAs assessed whether the number of psychotropic
medications was associated with higher mean levels of PB, TB, and suicide risk. Results
revealed non-significant differences in PB (F(9, 187) = 0.12, p = 0.73), TB (F(9, 187) =
1.49, p = 0.22), and suicide risk (F(9, 191) =0.50, p = 0.48) between individuals utilizing
one or no psychotropics and individuals utilizing two or more psychotropics (Table 5).
The third series of ANCOVAs assessed whether antipsychotic use was associated
with higher mean levels of PB, TB, and suicide risk relative to the use of other classes of
psychotropics. Results revealed a non-significant difference in PB (F(6, 89) = 1.29, p =
0.26), TB (F(7, 88) = 0.50, p = 0.48), and suicide risk (F(6, 92) = 0.016, p = 0.90; Table
6).
Exploratory Analyses
In an effort to increase specificity, exploratory analyses were conducted. These
analyses consisted of nine ANCOVAs, similar to the final three ANCOVAs used to test
our hypotheses regarding the use of an antipsychotic, with the difference being that the
predictor variable, antipsychotic use (versus other psychotropic medication), was
replaced with either antidepressant use, anxiolytic use, or mood stabilizer use (versus
other psychotropic medication use). PB, TB, and suicide risk served as the outcome
variables. Again, depression, anxiety, and BPD severity, and substance use were
included as covariates in addition to the demographics previously found to have either
between group differences for or significant associations with TB, PB, and suicide risk.
Additional demographic covariates were determined using both ANOVAs and Chi
Square tests prior to testing any hypotheses. Results indicated significant differences in
total family income for anxiolytic use (F(10, 101) = 3.74, p < 0.001) and a significant
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association between gender and mood stabilizer use (χ2(1, N = 112) = 5.66, p = 0.017).
Results revealed a significant difference in mean levels of PB (F(1, 91) = 4.59, p < 0.05)
between individuals utilizing antidepressants and individuals utilizing another
psychotropic other than an antidepressant. All other exploratory analyses yielded nonsignificant findings.

Table 4
Mean Differences between Individuals Utilizing a Psychotropic and Not Utilizing a Psychotropic on Suicidal Desire and Risk.

Burdensomeness
Belongingness
Suicide Risk

No Psychotropic Use
M
SD
11.78
8.32
17.76
7.22
2.59
5.72

Psychotropic Use
M
SD
11.08
7.08
18.53
7.56
5.82
9.64

F
0.07
0.02
9.62*

p
0.80
0.90
0.002

η2
0.00
0.00
0.05

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness:
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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Table 5
Mean Differences between Individuals Utilizing 0 or 1 Psychotropic and 2 or More Psychotropics on Suicidal Desire and Risk.

Burdensomeness
Belongingness
Suicide Risk

Use of 0 or 1
Psychotropic
M
SD
11.40
7.83
18.05
7.42
3.57
7.07

Use of 2 or More
Psychotropics
M
SD
11.58
7.29
18.57
7.31
6.95
11.14

F
0.12
1.49
0.50

p
0.73
0.22
0.48

η2
0.00
0.01
0.00

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness:
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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Table 6
Mean Differences between Individuals Utilizing an Antipsychotic and Individuals not Utilizing an Antipsychotic on Suicidal
Desire and Risk.

Burdensomeness
Belongingness
Suicide Risk

No Antipsychotic Use
M
SD
10.42
6.46
18.24
7.48
5.54
9.44

Antipsychotic Use
M
SD
12.80
7.47
20.11
7.86
6.82
10.76

F
1.29
0.50
0.02

p
0.26
0.48
0.90

η2
0.01
0.01
0.00

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness:
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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Table 7
Mean Differences between Individuals Utilizing an Antidepressant and Individuals not Utilizing an Antidepressant on Suicidal
Desire and Risk.

Burdensomeness
Belongingness
Suicide Risk

No Antidepressant
Use
M
SD
12.72
7.77
18.67
6.93
6.70
9.34

Antidepressant Use
M
10.54
18.49
5.49

SD
6.81
7.79
9.79

F
4.59
1.21
2.59

p
0.035
0.27
0.11

η2
0.048
0.013
0.027

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness:
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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Table 8
Mean Differences between Individuals Utilizing an Anxiolytic and Individuals not Utilizing an Anxiolytic on Suicidal Desire
and Risk.

Burdensomeness
Belongingness
Suicide Risk

No Anxiolytic Use
M
SD
11.42
7.36
18.77
7.78
5.87
10.05

Anxiolytic Use
M
SD
9.86
5.98
17.68
6.82
5.63
8.17

F
0.15
0.061
2.96

p
0.70
0.81
0.089

η2
0.002
0.001
0.031

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted
Belongingness: Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness
Thwarted Belongingness and Suicide Risk, but tests of between group differences are drawn from transformed totals.
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Table 9
Mean Differences between Individuals Utilizing a Mood Stabilizer and Individuals not Utilizing a Mood Stabilizer on Suicidal
Desire and Risk.

Burdensomeness
Belongingness
Suicide Risk

No Mood Stabilizer
Use
M
SD
10.96
7.19
18.18
7.53
5.61
9.45

Mood Stabilizer Use
M
11.61
20.05
6.58

SD
6.75
7.74
10.48

F
0.060
0.019
0.41

p
0.81
0.89
0.53

η2
0.001
0.000
0.004

Note: * = significant at p < .05, ** = significant at p < .001; Perceived Burdensomeness: Interpersonal Needs Questionnaire-Perceived Burdensomeness subscale; Thwarted Belongingness:
Interpersonal Needs Questionnaire-Thwarted Belongingness subscale. Means and standard deviations reflect non-transformed Perceived Burdensomeness Thwarted Belongingness and
Suicide Risk, but tests of between group differences are drawn from transformed totals.
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CHAPTER IV
DISCUSSION
This study aimed to examine the relationship between psychotropic medication
usage and suicidal desire and risk. Specifically, this study aimed to indicate whether the
use of psychotropic medication, use of multiple psychotropic medications, and usage of
an antipsychotic were associated with heightened levels of PB, TB, and risk for suicide.
Results were mostly inconsistent with hypotheses; however, results supported the
hypothesis that the use of psychotropic medication would result in a higher overall risk
for suicide. Additional exploratory analyses also revealed that the use of an
antidepressant resulted in lower levels of PB than the use of any other class of
psychotropic medication.
As expected, risk for suicide significantly differed between individuals utilizing
psychotropic medication(s) and individuals not utilizing psychotropic medication.
Individuals utilizing psychotropics exhibited higher mean levels for suicide risk than
individuals not utilizing psychotropics (non-transformed means = 5.82 versus 2.59),
suggesting that individuals utilizing a psychotropic are at an increased risk for suicide
relative to individuals not utilizing a psychotropic, even after accounting for the severity
of the psychopathology that prompted the prescription of the medication(s).
The non-significant difference in levels of PB and TB as a result of both
psychotropic medication use and use of multiple psychotropics may be due to the sample
composition, as the majority of the sample for this study was comprised of individuals
who identified as White/Caucasian and marginally consisted of more females than males.
Furthermore, the majority of individuals utilizing psychotropic medications were
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White/Caucasian females. The negative stigma associated with the use of psychotropic
medication may be diminished or even nonexistent for women and certain racial/ethnic
groups. Specifically, the use of psychotropic medications by white females may not be
associated with a negative stigma among such individuals because of its prevalent use
within this gender. A study examining the trends in psychotropic medication use
discovered that utilization of an antidepressant within females was twice the rate of that
in males (Paulose-Ram, Safran, Jonas, Gu, & Orwig, 2007). Furthermore, non-Hispanic
white individuals had a higher utilization rate relative to non-Hispanic blacks and
Mexican-Americans, specifically, non-Hispanic blacks and Mexican-Americans utilized
antidepressants 55% and 67% less than non-Hispanic whites.
The lack of significant findings may also be due to the measure of PB and TB
utilized. The questions within the INQ prompt participants to consider their feelings
within a recent timeframe (i.e. “these days”), implying that responses reference feelings
which were active in the here and now, rather than within their lifetime or even the recent
past. It is possible that participants’ levels of PB and TB may have decreased upon entry
into the treatment facility, especially given the fact that participants were required to
undergo detox for a period of time prior to entry into the facility. This explanation is
underscored by the finding of a significant difference in suicide risk between individuals
utilizing a psychotropic and individuals not utilizing a psychotropic, as the MINI
examines past moth and lifetime frequency; thus, suggesting that psychotropic
medication use was related to suicide when assessed within a broader timeframe. It is
also possible that the relationship between psychotropic medication use and suicide is
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independent of TB and PB, operating through different mechanisms not considered
within the proposed model.
Another possible explanation for the lack of significances may be the setting in
which the study was conducted. All participants within this study resided at a residential
treatment facility during the study. Psychotropic medication use was typical among
participants, as 49.8% of participants utilized a psychotropic medication; thus, the use of
a psychotropic medication may be considered more socially acceptable within this
particular setting. This explanation is analogous with Fife et al.’s (2012) finding that
psychiatric and substance abuse outpatients displayed more favorable attitudes regarding
the use of psychotropic medication relative to individuals never having utilized a
psychotropic medication.
An additional interpretation of these results might be that the relationship
between suicide risk and psychotropic medication is bidirectional. It may be more likely
that a psychotropic medication is frequently prescribed in response to an overt
endorsement of suicide (e.g., a prior suicide attempt), whereas report of a broader
vulnerability (i.e. TB or PB) may be less likely to prompt the prescription of psychotropic
medication.
Although unexpected, levels of PB significantly differed among
individuals utilizing antidepressants and individuals utilizing another type of
psychotropic, with individuals utilizing antidepressants displaying lower mean levels of
PB (10.54 Vs. 12.72). This significant difference implies that individuals utilizing
antidepressants experience reduced feelings of PB. Further, these findings suggest that
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the relationship between psychotropics and suicidality may not be explained by either the
side effects or stigmas associated with such medication.
Findings from the current study should be considered within the context of
their limitations. As noted before, one such limitation was the sample composition. The
generalizability of our results to populations other than SUD inpatient populations is
unclear. Additionally, inter-rater reliability for the structured interviews utilized in this
study was unavailable. Future studies should replicate these procedures in various
populations and establish inter-rater reliability for structured interviews.
Despite these limitations, this study has significant scientific and clinical
implications. Scientifically, the data provide evidence that psychotropic medication use
may increase an individual’s risk for suicide. Furthermore, the study indicates a need for
future research examining the mechanisms influencing the relationship between
psychotropic medication and suicide. Clinically, the findings from this study may serve to
increase awareness among prescribing physicians and clinicians, in turn prompting
physicians and clinicians to perform routine suicide risk assessments for individuals
utilizing psychotropic medication(s).
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